Verona Pharma plc - American Depositary Share (VRNA) News
Filter VRNA News Items
VRNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VRNA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VRNA News From Around the Web
Below are the latest news stories about VERONA PHARMA PLC that investors may wish to consider to help them evaluate VRNA as an investment opportunity.
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Analysts Expect Breakeven For Verona Pharma plc (NASDAQ:VRNA) Before LongVerona Pharma plc ( NASDAQ:VRNA ) is possibly approaching a major achievement in its business, so we would like to... |
Verona Pharma (VRNA) is on the Move, Here's Why the Trend Could be SustainableIf you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial HighlightsApproximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces prelim |
Verona Pharma Announces December 2024 Investor Conference ParticipationLONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 12:00 p.m. ET / 5:00 p.m. GMTLocation: New York, NY 7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Time: 3:00 p.m. ET / 8:00 p.m. GMTLocation: Miami, |
Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 yearsFor many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock... |
Verona Pharma PLC (VRNA) Q3 2024 Earnings Call Highlights: Strong Ohtuvayre Launch Amid Rising CostsVerona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market. |
Verona Pharma to Present at Jefferies London Healthcare ConferenceLONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com. For further information please contact: Verona P |
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOhtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focu |
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's WhyVerona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |